Regeneron to Participate in Guggenheim Biopharma Strategy Series

Rhea-AI Summary

Regeneron Pharmaceuticals (NASDAQ: REGN) will participate in a virtual fireside chat at the Guggenheim Biopharma Strategy Series on June 29, 2021, at 10:00 a.m. ET. The event will focus on global strategy and innovation in biopharma.

A live audio webcast can be accessed via Regeneron's 'Investors and Media' webpage, with an archived replay available for 30 days post-event. Regeneron is renowned for its innovative medicines addressing serious diseases, with a robust pipeline supported by advanced technologies like VelociSuite®.

TARRYTOWN, N.Y., June 22, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is scheduled to participate in a virtual fireside chat at the Guggenheim Biopharma Strategy Series – Biopharma's Next Decade: Views from the Top on Global Strategy and Innovation – at 10:00 a.m. ET on Tuesday, June 29, 2021.   

A live audio webcast will be available on the 'Investors and Media' page of Regeneron's website at http://investor.regeneron.com/events-and-presentations.  A replay of the conference call and webcast will be archived on the Company's website for at least 30 days. 

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite^® technologies, such as VelocImmune^®, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Contact Information:
Investor Relations
Justin Holko
914.847.7786
justin.holko@regeneron.com

 

View original content:http://www.prnewswire.com/news-releases/regeneron-to-participate-in-guggenheim-biopharma-strategy-series-301317654.html

SOURCE Regeneron Pharmaceuticals, Inc.

FAQ

What is the date and time of Regeneron's participation in the Guggenheim Biopharma Strategy Series?

Regeneron will participate on June 29, 2021, at 10:00 a.m. ET.

Where can I watch the live webcast of Regeneron's event?

The live audio webcast is available on the 'Investors and Media' page of Regeneron's website.

How long will the Regeneron conference call replay be available?

The replay of the conference call and webcast will be archived for at least 30 days.

What is Regeneron's focus in biopharmaceuticals?

Regeneron focuses on developing life-transforming medicines for serious diseases, with an extensive pipeline of treatments.

Which technologies does Regeneron use for drug development?

Regeneron uses technologies such as VelociSuite®, including VelocImmune®, to enhance drug development.